Gerresheimer
Thesis
Gerresheimer, a pharmaceutical packaging manufacturer, has seen significant improvements in growth prospects under new management and is positioned to benefit from the emerging GLP-1 growth opportunity. Despite these advancements, the company still trades at a discount compared to its competitors in the pharmaceutical packaging industry.
Did it work?
No price performance is available and the time elapsed since the pitch is unknown, so the return cannot be weighed against the long thesis or its implied re-rating horizon. While Gerresheimer did publicly pursue GLP-1-related pen-system opportunities, without knowing the pitch date or the stock's subsequent performance it is impossible to confirm whether the growth-improvement and valuation-discount thesis actually played out or was invalidated.